Journal article
T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma
Abstract
B-cell maturation antigen (BCMA) is a clinically validated target for multiple myeloma. T-cell engineered with chimeric antigen receptors (CARs) directed against BCMA have demonstrated robust therapeutic activity in clinical trials, but toxicities remain a significant concern for a subset of patients, supporting continued investigation of other engineered T-cell platforms that may offer equal efficacy with an improved toxicity profile. The …
Authors
Bezverbnaya K; Hammill JA; Cummings D; Bojovic B; Groisman B; Baker CL; Aarts C; Hayes DL; Rill D; Xu SX
Journal
Cytotherapy, Vol. 25, No. 5, pp. 490–501
Publisher
Elsevier
Publication Date
May 2023
DOI
10.1016/j.jcyt.2023.01.002
ISSN
1465-3249